drugset / Trial / NCT02394340
Study Evaluating the Drug Interaction Potential of Luliconazole Cream 1% in Participants With Tinea Pedis and Tinea Cruris
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label, maximal use study to evaluate whether luliconazole in plasma acts as an inhibitor of cytochrome P2C19 (CYP2C19) as measured by circulating levels of omeprazole before and after treatment with a maximum dose of luliconazole cream 1% in participants with moderate to severe tinea pedis and tinea cruris.
Timeline
- Start
- 2015-02-03
- Primary completion
- 2015-04-01
- Completion
- 2015-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Luliconazole | Small molecule | 1 % | Topical |
| Subject | Omeprazole | Other / unclassified | 40 mg | Oral |